Our Extended Family of Portfolio Companies

Investing in transformational ideas and entrepreneurial grit to solve major unmet needs in patient care

view more →

AN2 Therapeutics is a clinical-stage biotech company advancing novel small molecule therapeutics.

view more →

Developer of scientific data management software designed to enhance workplace collaboration. Acquired by PerkinElmer (NYS: PKI) in March 2011.

view more →

Bivarus is a healthcare IT company that has developed an elegant and efficient patient survey platform. Acquired by Press Ganey Associates in January 2018.

view more →

Clearside Biomedical is a biopharmaceutical company focused on revolutionizing treatment for sight-threatening back-of-the-eye diseases. IPO in June, 2016 (NASDAQ:CLSD).

view more →

Clinipace is a clinical research organization whose services are enhanced by a proprietary on-demand software platform and clinical research services. Acquired by dMed in April 2021.

view more →

Developer of an online platform for clinical payments. Acquired by BioClinica on January 19, 2016.

view more →

Curoverse developed a genomic and biomedical computing platform. Acquired by Veritas Genetics in August 2017.

view more →

CVRx develops an implantable system that delivers baroreflex activation therapy. IPO in June 2021 (NASDAQ: CVRX).

view more →

Developer of a technology designed to extract highly sensitive nucleic acid quantification. Acquired by Bio-Rad 2021

view more →

Developer of a system to enhance embolic cerebral protection. Acquired by Edwards Lifesciences (NYSE: EW) in March 2011.

view more →

G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company. IPO in May 2017 (NASDAQ: GTHX) Acquired by Pharmacosmos in 2024

view more →

Graybug Vision, Inc. was a clinical-stage ophthalmology company developing sustained-release therapies. IPO in September 2020 (NASDAQ: GRAY).

view more →

HistoSonics, Inc. is pioneering a novel, non-invasive therapeutic platform based on histotripsy. Acquired by Bezos Expeditions, Wellington K5 Global 2025

view more →

Engages patients and families in a personalized way to initiate discussions on end-of-life care planning. Acquired by Aledade in January 2022.

view more →

Founded by pediatricians, developing medical content in an educational format embraced by children. Acquired by Falfurrias 2024

view more →

Kymera Therapeutics, Inc. is a clinical-stage biotechnology company pioneering targeted protein degradation. IPO in August 2020 (NASDAQ: KYMR).

view more →

Developer of innovative neurodegeneration small-molecules intended to establish a platform for novel drug discovery.Acquired by Bial in October 2020.

view more →

Provider of patient experience platform designed to facilitate the relationship between physicians and patients. Acquired by NextGen 2019

view more →

Developer of staffing, communication and schedule management tools designed to modernize staffing processes. Acquired by HealthStream 2020

view more →

The Company’s lead product candidate, PB2452, is a novel reversal agent for the antiplatelet drug ticagrelor. IPO in October, 2018 (NASDAQ:PHAS)

view more →

Qpex Biopharma is a clinical-stage biopharmaceutical company developing novel anti-infective therapies. Acquired by Shionogi 2023

view more →

Rodin Therapeutics was a biotechnology company focused on discovering and developing first-in-class small molecule therapeutics. Acquired by ALKS in Nov 2019

view more →

Shattuck Labs is a clinical-stage biotechnology company advancing novel biologic medicines for inflammatory and immune-mediated diseases. IPO in October 2020 (NASDAQ: STTK)

view more →

Standard Bariatrics is a medical device company focused on advancing bariatric surgery.

view more →

Stridebio is developing engineered viral vectors for gene therapy. Acquired by Ginkgo Bioworks 2023

view more →

The company’s lead drug has potential to be a game-changer in the treatment of HITT. Acquired by Cadrenal Therapeutics 2025

view more →

Viamet Pharmaceuticals is a biotechnology company. Acquired by NovaQuest Capital Management in January 2018.

view more →

Vigil Neuroscience is a clinical-stage biotechnology company. IPO in January 2022 (NASDAQ: VIGL). Acquired by Sanofi in 2025.

“It is not the critic who counts: not the man who points out how the strong man stumbles or where the doer of deeds could have done better. The credit belongs to the man who is actually in the arena, whose face is marred by dust and sweat and blood, who strives valiantly, who errs and comes up short again and again, because there is no effort without error or shortcoming, but who knows the great enthusiasms, the great devotions, who spends himself in a worthy cause; who, at the best, knows, in the end, the triumph of high achievement, and who, at the worst, if he fails, at least he fails while daring greatly, so that his place shall never be with those cold and timid souls who knew neither victory nor defeat.”


Theodore Roosevelt
Speech at the Sorbonne, Paris, April 23, 1910